A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Cervical dysplasia is a condition characterized by the abnormal growth of cells on the surface of the cervix, indicating either precancerous or cancerous cells. The condition is classified as low-grade or high-grade, depending on the extent of the abnormal cell growth. Low-grade cervical dysplasia progresses very slowly and typically resolves on its own. High-grade cervical dysplasia can lead to cervical cancer. Without treatment, 30 - 50% of cases of severe cervical dysplasia progress to invasive cancer. The risk of cancer is lower for mild dysplasia. Currently, 11% of U.S. women report that they do not have regular cervical cancer screenings.
Cervical dysplasia often produces no symptoms and is usually discovered during an annual Pap smear.
Occasional signs and symptoms of the condition can include:
It is important to note that these symptoms are not unique to cervical dysplasia and they may indicate a different problem. If you are experiencing any of these signs or symptoms, you should see your doctor for an accurate diagnosis.
The precise cause of cervical dysplasia is not known. Studies have found a strong association between cervical dysplasia and infection with human papillomavirus (HPV), but additional factors (still unknown) must also be at play in order for cervical cells to change and become precancerous.
The following may increase an individual's risk for developing cervical dysplasia:
If any of the symptoms mentioned earlier are present, the physician will perform a physical, including an abdominal, back, and pelvic examination. As part of the pelvic exam, a Pap smear will be performed to detect precancerous or cancerous cells in the cervix. A Pap smear is also performed annually for screening purposes even when no symptoms are present. This test may be performed more or less often than once a year, depending on your individual medical history and risk factors for cervical cancer. For example, a woman who has had abnormal Pap smears in the past may need more tests than a woman who has always had normal Pap smears. But, if you have had normal pap smears 3 years in a row and you are over age 30, your doctor may perform a pap smear test only every 2 - 3 years, and only when your doctor suggests it is safe to wait that long between tests. If there are any questionable or unclear results from the Pap smear, a gynecologist will perform one of the following tests:
While there is no established strategy for preventing cervical dysplasia, regular Pap smears are the most effective and reliable method of identifying the condition in its early stages. Such early detection is key to preventing the condition from progressing to cervical cancer. Women should begin receiving annual Pap smears as soon as they become sexually active or no later than age 21. Women whose mothers took DES during pregnancy are advised to begin regular Pap smears at age 14, at the onset of their first menstrual period, or as soon as they become sexually active, whichever comes first.
Barrier contraceptives, such as condoms, may offer some degree of protection from cervical dysplasia.
The FDA has approved a vaccine, Gardasil, for human papillomavirus (HPV) for females 9 - 26 years of age to prevent cervical cancer. The Center for Disease Control' s National Immunization Program (NIP) and the federal Advisory Committee on Immunization Practices have recommended the use of the vaccine. Although the vaccine could prevent up to 70% of cervical cancer cases, it cannot prevent infection with every virus that causes cervical cancer. Routine Pap tests to screen for cervical cancer remain very important.
Some lifestyle modifications may also help prevent the development of cervical dysplasia:
An important consideration in deciding whether or not to treat cervical dysplasia is how the treatment may affect future fertility. There are no good studies investigating infertility after treatment for cervical dysplasia, but there is some evidence of increased risk of preterm delivery among pregnant women. Surgical removal of abnormal tissue is still the treatment of choice for cervical dysplasia. Medications are not used to treat cervical dysplasia, and few complementary or alternative therapies have been evaluated for their effectiveness in treating the condition. Several studies indicate, however, that the development and progression of cervical dysplasia may be related to certain nutritional deficiencies, including folate, beta-carotene, and vitamin C.
Medications are not used to treat cervical dysplasia.
Surgical removal of abnormal tissue is the most common method of treating cervical dysplasia. Ninety percent of these procedures can be done in an outpatient setting. These procedures include:
Following these nutritional tips may help reduce the chances of developing cervical dysplasia, however, any nutritional interventions should be cleared by your doctor. Some nutrients can interfere with certain medications and procedures.
Nutritional deficiencies may be addressed with the following supplements:
Herbs are generally a safe way to strengthen and tone the body's systems. As with any therapy, you should work with your health care provider to diagnose your problem before starting any treatment. You may use herbs as dried extracts (capsules, powders, teas), glycerites (glycerine extracts), or tinctures (alcohol extracts). Unless otherwise indicated, make teas with 1 tsp. herb per cup of hot water. Steep covered 5 - 10 minutes for leaf or flowers, and 10 - 20 minutes for roots. Drink 2 - 4 cups per day. You may use tinctures alone or in combination as noted.
Several population-based studies suggest that eating a diet rich in the following nutrients from fruits and vegetables may protect against the development of cervical cancer:
Beta-carotene
Some controversial clinical studies suggest that individuals deficient in beta-carotene may be more likely to develop cancerous or precancerous cervical lesions, but this relationship remains inconclusive. Other studies indicate that oral supplementation with beta-carotene may promote a decline in the signs of cervical dysplasia. Despite these promising results, the benefit of using beta-carotene supplements to prevent the development of cervical dysplasia or cervical cancer has not been proven.
Supplemental beta-carotene may increase the risk of lung cancer, prostate cancer, intracerebral hemorrhage, and cardiovascular and total mortality in people who smoke cigarettes or have a history of high-level exposure to asbestos. Beta-carotene from foods does not seem to have this effect.
Folate (Vitamin B9)
Like beta-carotene, some evidence suggests that folate (also known as vitamin B9) deficiencies may contribute to the development of cancerous or precancerous lesions in the cervix. Researchers also theorize that folate consumed in the diet may improve the cellular changes seen in cervical dysplasia by lowering homocysteine (a substance believed to contribute to the severity of cervical dysplasia) levels. The benefit of using dietary folate to prevent or treat cervical dysplasia has not been sufficiently proven.
Castor Oil Packs
Dampen a cloth with castor oil and apply to the abdomen. Cover with saran wrap and then apply a heating pad over this pack. Used for 1 - 3 hours, castor oil packs can reduce cramping and pain in some patients.
Pregnancy
Pap smears are essential to detecting precancerous lesions as well as early stages of cervical cancer. The regular use of Pap smears as a screening test has prevented millions of cases of cervical cancer and has saved a similar number of lives. Despite their value, they are not always 100% accurate. Up to 2% of women with normal Pap smear results actually have high-grade cervical dysplasia at the time of evaluation. In some rare cases, Pap smears may produce "false positive" results, meaning that a healthy woman may be falsely diagnosed with cervical dysplasia. Despite these errors, Pap smears are the most effective and reliable method of identifying cervical dysplasia.
Cervical cancer, a major complication of cervical dysplasia, is the leading cause of death in many developing and poorer countries and accounts for 4,800 deaths in the United States every year. Most cervical cancer deaths occur in women who have not had a Pap smear. Cervical cancer constitutes more than 10% of cancers worldwide, and it is the second leading cause of death in women between the ages of 15 - 34.
With early identification, treatment, and consistent follow-up, nearly all cases of cervical dysplasia can be cured. Without treatment, many cervical dysplasia cases progress to cancer. Women who have been treated for cervical dysplasia have a lifetime risk for recurrence and malignancy. Fortunately, while the incidence of cervical dysplasia has been on the rise, the incidence of cervical cancer has declined dramatically. This may be due to improved screening techniques, which identify cases of cervical dysplasia in the early stages, before they have progressed to cancer.
Cancer - cervical; Cervical cancer; Pap smear - abnormal
Antony S, Kuttan R, Kuttan G. Effect of Viscum album in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells. J Exp Clin Cancer Res. 1997;16(2):159-162.
Apgar BS, Brotzman G. HPV testing in the evaluation of the minimally abnormal Papanicolaou smear. Am Fam Physician. 1999;59(10):2794-2801.
Batieha AM, Armenian HK, Norkus EP, Morris JS, Spate VE, Comstock GW. Serum micronutrients and the subsequent risk of cervical cancer in a population-based nested case-control study. Cancer Epidemiol Biomarkers Prev. 1993;2(4):335-339.
Butterworth CE Jr, Hatch KD, Soong SJ, et al. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol. 1992(b);166(3):803-809.
Comerci JT Jr, Runowicz CD, Fields AL, et al. Induction of transforming growth factor-beta1 in cervical intraepithelial neoplasia in vivo after treatment with beta-carotene. Clin Cancer Res. 1997;3(2):157-160.
Cox JT. Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings. JAMA. 1999;281(17):1645-1647.
Fairley CK, Tabrizi SN, Chen S, et al. A randomised clinical trial of beta-carotene vs placebo for the treatment of cervical HPV infection. Int J Gynecol Cancer. 1996;6:225-230.
Gingelmaier A, Grubert T, Kaestner R, et al., High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women. Anticancer Res. 2007;27(4A):1795-8.
Giuliano AR, Gapstur S. Can cervical dysplasia and cancer be prevented with nutrients? Nutr Rev. 1998;56(1):9-16.
Goodman MT, McDuffie K, Hernandez B, Wilkens LR, Selhub J. Case-control study of plasma folate, homocysteine, vitamin B12, and cysteine as markers of cervical dysplasia. Cancer. 2000;89(2):376-382.
Hernandez BY, McDuffie K, Franke AA, Killeen J, Goodman MT. Reports: plasma and dietary phytoestrogens and risk of premalignant lesions of the cervix. Nutr Cancer. 2004;49(2):109-24.
Hernandez BY, McDuffie K, Wilkens LR, Kamemoto L, Goodman MT. Diet and premalignant lesions of the cervix: evidence of a protective role for folate, riboflavin, thiamin, and vitamin B12. Cancer Causes Control. 2003;14(9):859-70.Kim YT, Kim JW, Choi JS, Kim SH, Choi EK, Cho NH. Relation between deranged antioxidant system and cervical neoplasia. Int J Gynecol Cancer. 2004;14(5):889-95.
Kuttan G, Menon LG, Kuttan R. Prevention of 20-methylcholanthrene-induced sarcoma by a mistletoe extract, Iscador. Carcinogenesis. 1996;17(5):1107-1109.
Kwasniewska A, Tukendorf A, Semczuk M. Folate deficiency and cervical intraepithelial neoplasia. Eur J Gynaecol Oncol. 1997;18(6):526-530.
Lee KE, Koh CF, Watt WF. Comparison of the grade of CIN in colposcopically directed biopsies with that in outpatient loop electrosurgical excision procedure (LEEP) specimens -- a retrospective review. Singapore Med J 1999;40(11):694-696.
Liao SY, Stanbridge EJ. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia. Cancer. 2000;88(5):1108-1121.
Mackerras D, Irwig L, Simpson JM, et al. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer. 1999;79(9-10):1448-1453.
Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 1999;281(17):1605-1610.
Moore KN, Bannon RJ, Lanneau GS, Zuna RE, Walker JL, Gold MA. Cervical dysplasia among women over 35 years of age. Am J Obstet and Gynecol. 199(5):471.e1-5.
Nagata C, Shimizu H, Higashiiwai H, et al. Serum retinol level and risk of subsequent cervical cancer in cases with cervical dysplasia. Cancer Invest. 1999;17(4):253-258.
Nagata C, Shimizu H, Yoshikawa H, et al. Serum carotenoids and vitamins and risk of cervical dysplasia from a case-control study in Japan. Br J Cancer. 1999;81(7):1234-1237.
Paavonen J, Jenkins D, Bosch FX, et al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161-70.
Peng YM, Peng YS, Childers JM, et al. Concentrations of carotenoids, tocopherols, and retinol in paired plasma and cervical tissue of patients with cervical cancer, precancer, and noncancerous diseases. Cancer Epidemiol Biomarkers Prev. 1998;7(4):347-350.
Perlman SE. Pap smears: screening, interpretation, treatment. Adolesc Med. 1999;10(2):243-254.
Piyathilake CJ, Henao OL, Macaluso M, Cornwell PE, Meleth S, Heimburger DC, Partridge EE. Folate is associated with the natural history of high-risk human papillomaviruses. Cancer Res. 2004;64(23):8788-93.
Qi M, Anderson AE, Chen DZ, Sun S, Auborn KJ. Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Mol Med. 2005;11(1-12):59-63.
Hudspeth, R. Ratcliffe: Family Medicine Obstetrics, 3rd ed. Mosby Elsevier: Philadelphia, PA. 2008.
Rock CL, Michael CW, Reynolds RK, Ruffin MT. Prevention of cervix cancer. Crit Rev Oncol Hematol. 2000;33(3):169-185.
Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52(6):342-362.
Schaefermeyer G, Schaefermeyer H. Treatment of pancreatic cancer with Viscum album (Iscador): a restrospective study of 292 patients 1986-1996. Complement TherMed. 1998;6:172-177.
Sedjo RL, Inserra P, Abrahamsen M, et al. Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women. Cancer Epidemiol Biomarkers Prev. 2002;11(4):353-359.
Stanley MA. Human papillomavirus vaccines. Rev Med Virol. 2006;16(3):139-49.
Thomson SW, Heimburger DC, Cornwell PE, et al. Correlates of total plasma homocysteine: folic acid, copper, and cervical dysplasia. Nutrition. 2000;16(6):411-416.
Trimble CL, Genkinger JM, Burke AE, et al., Active and passive cigarette smoking and the risk of cervical neoplasia. Obstet Gynecol. 2005;105(1):174-81.
Zsemlye M. High-Grade Cervical Dysplasia: Pathophysiology, Diagnosis, and Treatment. Obstet and Gynecol Clinics. 2008;35(4).
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.800.492.5538